Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial

医学 放射治疗 临床终点 放射外科 随机对照试验 核医学 外科
作者
Carole Mercier,Charlotte Billiet,Piet Ost,Katrien Vandecasteele,Geert De Kerf,Michaël Claessens,Steven Van Laere,Peter Vermeulen,Luc Yves Dirix,Yolande N. Lievens,Dirk Verellen,Piet R. Dirix
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (19): 2164-2172 被引量:17
标识
DOI:10.1200/jco-24-01447
摘要

PURPOSE To test whether dose-escalated single fraction (SF) stereotactic body radiotherapy (SBRT) of 20 Gy to painful bone metastases is superior to conventional SF three-dimensional (3D) conformal radiotherapy (RT) to a standard dose of 8 Gy in achieving complete pain response (CR). METHODS A single-blind, randomized, controlled, phase III trial (ROBOMET) included 126 patients with up to three painful bone metastases, randomly assigned between April 2019 and October 2022 at multiple centers in Belgium. Inclusion criteria were uncomplicated painful bone metastases (worst pain score ≥2 on a 0-10 pain scale) arising from a solid tumor. Treatment consisted of either a single SBRT fraction of 20 Gy or a single conventional RT fraction of 8 Gy. The primary end point was the proportion of patients with a CR 1 month after RT scored according to the International Consensus on Palliative Radiotherapy Endpoints analyzed as per an intention-to-treat principle. RESULTS After 1 month, 16 of 63 (25% [95% CI, 15 to 38]) patients treated with conventional RT achieved CR versus 23 of 63 (37% [95% CI, 25 to 50]) treated with SBRT ( P = .25). After 3 months, 15 of 63 (24% [95% CI, 14 to 36]) patients achieved CR after conventional RT versus 21 of 63 (33% [95% CI, 22 to 46]) after SBRT ( P = .32). Among patients evaluable after 3 months and treated per protocol, the SBRT group had more complete responders (21/39, 54% [95% CI, 37 to 70]) than the conventional RT group (15/48, 31% [95% CI, 19 to 46]; P = .048). CONCLUSION SBRT failed to demonstrate improved CR rates after 1 month.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
daomaihu发布了新的文献求助100
1秒前
今后的应助被马大海采纳,获得10
1秒前
worldlet发布了新的文献求助10
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
科目三的应助被科研通管家采纳,获得10
2秒前
无花果的应助被科研通管家采纳,获得10
2秒前
fan的应助被科研通管家采纳,获得10
2秒前
充电宝的应助被科研通管家采纳,获得10
2秒前
null的应助被科研通管家采纳,获得10
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
小蘑菇的应助被科研通管家采纳,获得10
2秒前
null的应助被科研通管家采纳,获得10
2秒前
TH发布了新的文献求助30
2秒前
Akim的应助被科研通管家采纳,获得10
3秒前
赘婿的应助被科研通管家采纳,获得10
3秒前
inspire的应助被科研通管家采纳,获得10
3秒前
3秒前
大个的应助被科研通管家采纳,获得10
3秒前
3秒前
3秒前
余香的应助被科研通管家采纳,获得10
3秒前
香蕉觅云的应助被科研通管家采纳,获得30
3秒前
muxiangrong的应助被科研通管家采纳,获得10
4秒前
李爱国的应助被科研通管家采纳,获得10
4秒前
Orange的应助被科研通管家采纳,获得10
4秒前
TED的应助被科研通管家采纳,获得10
4秒前
江河湖海完成签到,获得积分10
4秒前
初景的应助被科研通管家采纳,获得20
4秒前
领导范儿的应助被科研通管家采纳,获得10
4秒前
null的应助被科研通管家采纳,获得10
4秒前
打打的应助被科研通管家采纳,获得10
5秒前
5秒前
NexusExplorer的应助被科研通管家采纳,获得10
5秒前
5秒前
5秒前
狂野的小熊猫的应助被Zz采纳,获得10
5秒前
5秒前
田様的应助被andjdd采纳,获得10
6秒前
Jasper的应助被ZDC采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184336
求助须知:如何正确求助?哪些是违规求助? 9573358
关于积分的说明 21830993
捐赠科研通 7781367
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558401
邀请新用户注册赠送积分活动 2480846